Our Vision
We drive growth by improving access to specialty CNS medicines for patients and clinicians across Europe and beyond.
Tell Me More


LATUDA® (lurasidone)

CNX Therapeutics currently markets lurasidone in the UK and selected countries in Europe.

Adverse reactions should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk

Adverse reactions should also be reported to CNX Therapeutics on +44 (0) 20 7821 2899.

For more information about lurasidone visit:

About Us

CNX Therapeutics is a Specialty, European Pharmaceutical Company dedicated to the treatment of CNS disorders.

In 2021 Inflexion Private Equity Partners LLP a leading global investment firm, acquired the European subsidiary (now known as CNX Therapeutics) of a leading global CNS focused pharmaceutical company.

The goal of CNX Therapeutics is to build a successful European business which will commercialise CNS treatment options and become a specialist in this therapy area.

We currently commercialise and distribute (either directly or via our trusted partners) LATUDA® (lurasidone) in Europe, and seek to capitalise on this foundation by building a portfolio of CNS assets.

We will do this by:

  • Successfully leveraging our footprint and capabilities across Europe and beyond.
  • Being a trusted partner of choice for the out-licensing, and divestment of pharmaceutical products.
  • Striving to continually develop our people harnessing key skills and leveraging cross functional collaboration.

CNX Therapeutics has designed and successfully executed a relatively unique 'Hub & Spoke' business model (since 2014) which is now operating smoothly across 7 countries, and will continue to expand as the company grows. The 'hub' or European office of this business model is in London. We collaborate successfully with commercial alliance partners in Europe, Russia, Middle East and North Africa.

CNX Therapeutics will achieve its goals by embracing its core values:
Work as one team, Operate with high standards, Deliver on our commitments, Focus on bespoke solutions, Communicate openly and transparently and Empower our people.


London, July 29, 2022

CNX Therapeutics embarks on its buy-and-build strategy with first acquisition

CNX Therapeutics has successfully completed the acquisition of Synchrony Pharma, a company specialising in the development and commercialisation of niche injectable pharmaceuticals.

Read More »

Join Us

Come and Thrive at CNX Therapeutics.

With us you will have a broad challenging role that will make every day different and provides continuous learning opportunities.

Our "One Team" culture is open and transparent and builds ownership with a desire to win as a team. You can really make an impact with us and will be enabled by a fast working pace where decisions are made quickly. In return you will be recognised for your results via our attractive rewards package.

By joining CNX Therapeutics you will be part of a supportive team and will find your colleagues are passionate about the patient. If you enjoy new challenges and thrive on finding new solutions as we grow our company, then this is the place for you.

If you believe that you have the experience, qualifications, commitment and potential to join our team, please submit your current Curriculum Vitae to HumanResources@cnx-therapeutics.com. We will contact you if we have any roles which we feel would be appropriate to you.

Agency Policy

We are proud to hold good working relationships with a select number of preferred recruitment agencies. Please note that we do not accept unsolicited candidate submissions from recruitment agencies.


Code of Conduct

The Code of Conduct of CNX Therapeutics reflects the importance that we place on compliance and maintaining high ethical standards, at all times, as we operate our business.

The Code of Conduct summarises the standards that must guide our actions. All employees including our directors are required to adhere to its principles as they fulfil their responsibilities.

Contact Us

CNX Therapeutics

Correspondence address:
LABS House, 15-19 Bloomsbury Way,
London, WC1A 2TH

Registered address:
3 Bunhill Row,
London, EC1Y 8YZ

CNX Therapeutics is registered with the Telephone and Mail Preference services and has opted not to receive unsolicited sales or marketing calls or mail.

To Discuss Drug Safety or Report Adverse Events

Telephone: +44 (0) 20 7821 2899
Email: vigilance@cnx-therapeutics.com